Quanterix to Acquire Akoya Biosciences in an All-Stock Deal for $286.34 Million

Quanterix Corporation (QTRX) entered a merger agreement on January 10, 2025, to acquire Akoya Biosciences, Inc. (AKYA) in an all-stock deal valued at about $286.34 million, to create the first combined solution for highly sensitive detection of protein biomarkers in blood and tissue.

Deal Structure:

Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock they own, which is valued at approximately $3.73 per share, representing a premium of 40.23% from the stock’s last close.

Please subscribe for free or login to your InsideArbitrage account to access this article.